

#4
GND001 584
1/16/02

FISH & RICHARDSON P.C.

325 Franklin Street
Boston, Massachusetts
02110-2804Telephone
617 542-5070Facsimile
617 542-8906Web Site
www.fr.com**OFFICIAL**

Date January 16, 2002

To Examiner Jerry Ewoldt
U.S. Patent & Trademark Office
Commissioner for Patents
Washington, D.C. 20231

Facsimile number 12071-01000002 / (703) 746-5107

From Lee Crews, Ph.D.

Re Evidence of filing CONTINUATION
Our Ref.: 12071-010002
Application No.: 09/932,483
Filing Date: August 17, 2001Number of pages
including this page 7

Message Dear Examiner Ewoldt,

Following, in response to your telephone call yesterday, are: (1) copy of our transmittal letter for the application referenced above and (2) the official filing receipt we subsequently received.

Please do whatever is necessary to prevent this case from being marked abandoned.

If you require anything further, please call me.

Thanks for your help.

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at 617 542-5070 to arrange for its return. Thank you.

FIS. RICHARDSON P.C.

225 Franklin Street
Boston, Massachusetts
02110-2804

Telephone
617 542-5070

Facsimile
617 542-8906

Web Site
www.fr.com

Frederick P. Fish
1855-1930

August 17, 2001

W.K. Richardson
1859-1951

Attorney Docket No.: 12071-010002

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Presented for filing is a new continuation patent application of:

Applicant: ERWIN W. GELFAND, ANGELA FRANCISCA HACZKU AND
KATALIN VERONIKA LUKACS


Title: METHOD FOR TREATING INFLAMMATORY DISEASES USING
HEAT SHOCK PROTEINS

The prior application is assigned of record to:

Imperial College Innovations Ltd., and Institute of Cancer Research,
a research institution, by virtue of an assignment submitted to the Patent and
Trademark Office and recorded on July 9, 1998 at Reel 9311 and on Frame 0662;

Imperial College Innovations Ltd., and Institute of Cancer Research Royal Cancer
Hospital, a research institution, by virtue of an assignment submitted to the Patent and
Trademark Office and recorded on July 9, 1998 at Reel 9309 and on Frame 0256;

National Jewish Center For Immunology and Respiratory, a Colorado corporation, by
virtue of an assignment submitted to the Patent and Trademark Office and recorded
on July 9, 1998 at Reel 9309 and on Frame 0267;


BOSTON
DALLAS
DELAWARE
NEW YORK
SAN DIEGO
SILICON VALLEY
TWIN CITIES
WASHINGTON, DC

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EJ485677802US

I hereby certify under 37 CFR §1.10 that this correspondence is being
deposited with the United States Postal Service as Express Mail Post
Office to Addressee with sufficient postage on the date indicated below
and is addressed to the Commissioner for Patents, Washington,
D.C. 20231.

August 17, 2001
Date of Deposit

Diane M. Miles
Signature

Diane M. Miles
Typed or Printed Name of Person Signing Certificate

FISH F. HARDSON P.C.

Commissioner for Patents

August 17, 2001

Page 2

National Jewish Center For Immunology and Respiratory, a Colorado corporation, by virtue of an assignment submitted to the Patent and Trademark Office and recorded on July 13, 1998 at Reel 9311 and on Frame 0297; and

National Jewish Center For Medical and Research Center, a Colorado corporation, by virtue of an assignment submitted to the Patent and Trademark Office and recorded on July 13, 1998 at Reel 9334 and on Frame 0564.

Enclosed are the following papers, including those required to receive a filing date under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	81
Claims	14
Abstract	1
Declaration	6
Drawings	7

Enclosures:

- Form PTO-1449, 1 page, listing documents cited in the parent application. Please confirm that these have been considered in this application by returning a copy of the Form PTO-1449 with the examiner's initials.
- Small entity statement, 2 pages.
- Postcard.

This application is a continuation (and claims the benefit of priority under 35 USC § 120) of U.S. application serial no. 09/012,330, filed January 23, 1998. The entire disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

Basic filing fee	\$355
Total claims in excess of 20 times \$9	\$126
Independent claims in excess of 3 times \$40	\$0
Fee for multiple dependent claims	\$0
Total filing fee:	\$481

FISH & RICHARDSON P.C.

Commissioner for Patents
August 17, 2001
Page 3

The fee calculation shown above was made in view of the Preliminary Amendment filed herewith, rather than on the basis of the number of claims originally filed. A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.


If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at (617) 542-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

LEE CREWS
Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804

Respectfully submitted,


Lee Crews, Ph.D.
Reg. No. 43,567
Enclosures

20303382.doc

JKF

LLC



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/932,483	08/17/2001	1644	481	12071-010002	7	34	3

CONFIRMATION NO. 5360

FILING RECEIPT



OC00000008534723

LEE CREWS
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Date Mailed: 09/10/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Katalin Veronika Lukacs, London, UNITED KINGDOM;
Angela Francisca Haczku, Princeton Junction, NJ;
Erwin W. Gelfand, Englewood, CO;

Assignment For Published Patent Application

Imperial College Innovations Ltd.;
Institute of Cancer Research, a research institution;
Institute of Cancer Research Royal Cancer Hospital, a research institution;
National Jewish Center for Immunology and Respiratory, a Colorado corporation;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/012,330 01/23/1998

Foreign Applications

If Required, Foreign Filing License Granted 09/07/2001

Projected Publication Date: 12/20/2001

Non-Publication Request: No

Early Publication Request: No

RECEIVED
SEP 12 2001
FISH & RICHARDSON, P.C.
BOSTON OFFICE

* No Docketing Required *
Reviewed By Practice Systems
Initials: JEC
Reviewed By Filing Secretary
Initials:

**** SMALL ENTITY ****

Title

Method for treating inflammatory diseases using heat shock proteins

Preliminary Class

424

Data entry by : SEDIQEE, AHMADULLAH

Team : OIPE

Date: 09/10/2001

[illegible]

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231